<DOC>
	<DOCNO>NCT01791647</DOCNO>
	<brief_summary>The aim study compare effect six month treatment two insulin-lowering therapy clinical endocrine-metabolic parameter obese woman affect polycystic ovary syndrome . The study group include 40 patient , randomly allocate subgroup A ( metformin 1500 mg/day ) subgroup B ( myo-inositol 1500 mg/day ) . The investigation include menstrual pattern hirsutism score evaluation , hormonal assay , oral glucose tolerance test , euglycemic hyperinsulinaemic clamp lipid profile baseline six month treatment .</brief_summary>
	<brief_title>Myo-inositol Versus Metformin Obese Women With Polycystic Ovary Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Inositol</mesh_term>
	<criteria>woman Polycystic Ovary Syndrome , diagnose accordance Rotterdam Consensus Conference Criteria 2003 ; BMI &gt; 25 kg/m2 ; age 1835 year . pregnancy ; significant liver renal impairment ; hormonal dysfunction ( hypothalamic , pituitary , thyroidal adrenal cause clinical sign ) ; neoplasm ; unstable mental illness ; diagnosis diabetes mellitus impaired glucose tolerance ; use drug able interfere glucoinsulinaemic metabolism least three month prior enter study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Polycystic ovary syndrome</keyword>
	<keyword>myoinositol</keyword>
	<keyword>metformin</keyword>
	<keyword>glucose-insulinemic metabolism</keyword>
	<keyword>menstrual pattern</keyword>
	<keyword>insulin-lowering therapy</keyword>
</DOC>